Dihydrotachysterol.
Research-backed compound with potential health benefits. Raises blood calcium levels. It's a synthetic Vitamin D analog prescribed for specific conditions like hypoparathyroidism or calcium issues from chronic kidney disease.
Reviewed March 2026
- Category
- Compound
What Dihydrotachysterol is, and what it does.
- Does it work
- Only if prescribed by a doctor for a specific medical condition. For general Vitamin D needs or bone health? Absolutely not. Stick with standard Vitamin D3.
- How much to take
- Your doctor determines the dose based on your blood work. There is no 'standard' dose. Self-dosing is extremely dangerous.
- Time to feel it
- Blood calcium starts moving within days and settles over one to two weeks. It shows up on a blood panel rather than as a sensation, and it clears faster than standard vitamin D.
- The first dose
- Nothing. It acts slowly to regulate calcium, with effects building over days and weeks.
- With regular use
- Long-term misuse leads to severe health complications.
- How well tolerated
- Only safe under strict medical supervision with regular blood monitoring. High risk of hypercalcemia, which is a medical emergency.
- How it feels
- You don't feel the drug. You feel the absence of low-calcium symptoms over time. This is a treatment, not a wellness product.
- The overlooked benefit
- It skips the kidney activation step that cholecalciferol depends on, and it washes out of the body faster because it is held less tightly in fat and on its carrier protein.
0.2 to 0.5mg a day is where Dihydrotachysterol works.
Source: Prescription drug literature; Harrison's Principles of Internal Medicine
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Dihydrotachysterol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Intestinal calcium absorptionNarrative review
- Calcium and phosphate balance under blood monitoringNarrative review
- Bone mineral supplyNarrative review
Questions people ask about Dihydrotachysterol.
- Is this just a stronger Vitamin D?
- No. It's a synthetic analog that works differently and more potently on blood calcium. It's a drug, not a vitamin supplement.
- Can I take this for general bone health?
- No. For general bone health, use regular Vitamin D3 and calcium. This is for specific medical conditions causing low blood calcium.
- What happens if I take too much?
- You risk hypercalcemia (dangerously high blood calcium). Symptoms include nausea, weakness, confusion, and permanent kidney damage.
- Do I need a prescription for dihydrotachysterol?
- Yes. This is not an over-the-counter supplement in the United States and most other countries.
- Why use this instead of regular Vitamin D3?
- It doesn't require activation by the kidneys to work, making it effective for people with kidney disease who can't process standard Vitamin D.
- Can I buy this online without a script?
- Even if you find it, it's a terrible idea. Dosing requires professional monitoring and blood tests to be safe.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Dihydrotachysterol is a vitamin D analogue that is hydroxylated in the liver and acts at the vitamin D receptor to raise active intestinal calcium uptake. Its effect on calcium balance depends entirely on how much calcium is available in the gut at the same time.
Carbonate salts are the usual calcium source paired with a vitamin D analogue because the analogue raises the fraction absorbed by the active transcellular route. Carbonate needs stomach acid to dissociate, so it is taken with food for that reason.
The hydroxylase enzymes that activate vitamin D compounds and the transport protein that carries them are magnesium dependent. Low magnesium status blunts the conversion of dihydrotachysterol into its active hydroxylated form.
Vitamin D receptor activation raises intestinal uptake of phosphate alongside calcium, and bone mineral is laid down as a calcium phosphate lattice. Calcium and phosphate move together under this signal, so both sides of the pair matter.
Vitamin D signalling raises the amount of osteocalcin and matrix Gla protein made, and vitamin K2 supplies the carboxylation step that lets those proteins attach calcium. Pairing them means the extra calcium taken up is directed into mineralised tissue.
Both act through the same vitamin D receptor to raise calcium absorption, so their effects on calcium balance add rather than run in parallel. Total activity at that receptor should be read across both rather than dosed independently.
The vitamin D receptor works as a heterodimer with the retinoid X receptor, which retinoid metabolites also occupy. Large retinoid loads can shift that partnership and dampen vitamin D receptor driven gene activity.
Strontium moves through the same intestinal calcium channels and bone mineral sites that a vitamin D analogue makes more active. Taken together they compete for that route, which is why strontium is normally dosed away from calcium and vitamin D.
Boron affects the handling of calcium and magnesium and has been reported to influence circulating vitamin D metabolites in small human work. Dihydrotachysterol acts directly at the vitamin D receptor once hydroxylated in the liver. The overlap sits at the level of mineral handling and is not a measured combination.
Orthosilicic acid is involved in collagen matrix formation, the protein scaffold that mineral is deposited onto. A vitamin D receptor agonist raises the mineral supply side. The two address different halves of bone tissue and have not been trialled together.
Manganese is the cofactor for glycosyltransferases that build the proteoglycan ground substance of bone and cartilage. Without matrix there is nothing for absorbed calcium to be laid into. The cofactor relationship is textbook.
Lysyl oxidase is a copper-dependent enzyme that cross-links collagen fibrils, giving the bone matrix its tensile properties. Vitamin D receptor agonists increase calcium available for mineralisation but do nothing for cross-linking. The pairing covers both sides.
Alkaline phosphatase, the osteoblast enzyme that liberates phosphate at the mineralisation front, is a zinc metalloenzyme. Zinc also competes with copper for intestinal uptake, so the two are usually kept in a fixed ratio. Both facts are settled pharmacology.
Prolyl and lysyl hydroxylases need ascorbate to keep their iron centre reduced while they modify procollagen. Collagen is the organic scaffold of bone. Calcium supplied by a vitamin D receptor agonist has to be deposited onto that scaffold.
Vitamin K is the cofactor for gamma-glutamyl carboxylase, which adds the calcium-binding carboxyl groups to osteocalcin and matrix Gla protein. Those proteins are how calcium is incorporated into bone and kept out of soft tissue. An agonist that raises calcium absorption depends on that carboxylation step being supplied.
Lysine is the residue that lysyl oxidase cross-links in collagen and has been reported to affect intestinal calcium handling in small studies. Its role in the matrix side is settled; its effect on calcium uptake is thinner. The combination has not been trialled with this compound.
A vitamin D receptor agonist is normally taken alongside calcium, and calcium taken in the same sitting reduces non-heme iron uptake at the enterocyte. Separating the two by a few hours is the usual handling. The competition is with the calcium, not with the analogue itself.
Caffeine modestly increases urinary calcium loss over the hours after intake. That works against the calcium retention a vitamin D receptor agonist supports. The size of the effect is small at ordinary intakes and is offset by adequate calcium.
Sodium and calcium share reabsorption handling in the renal tubule, so a higher sodium load raises urinary calcium output. Anything raising calcium absorption is partly offset by that loss. This is settled renal physiology.
Potassium salts of organic anions generate bicarbonate and reduce urinary calcium excretion, the opposite direction to a high sodium load. A vitamin D receptor agonist increases calcium entering the body; the potassium effect concerns how much is kept. The two act at different points.
Nothing specific on file for Dihydrotachysterol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Dihydrotachysterol actually does.
Dihydrotachysterol is a reduced vitamin D analogue whose A-ring is rotated, so its 3-hydroxyl group occupies a spatial position resembling the 1-hydroxyl of the fully active hormone.
It is 25-hydroxylated in the liver, and the resulting 25-hydroxydihydrotachysterol binds the vitamin D receptor without requiring the renal 1-alpha-hydroxylation step that cholecalciferol depends on.
Vitamin D receptor occupancy increases intestinal calcium uptake through calbindin and the TRPV6 channel and increases phosphate absorption alongside it.
Any second vitamin D receptor agonist taken at the same time acts on the same receptor, so the effects on serum calcium are additive rather than independent.
The forms it comes in.
The essence, in one line each.
- Among adults on long-term calcium and vitamin D analogue management following neck surgery, symptom burden remained substantial on conventional management; dihydrotachysterol is named among the analogues used rather than analysed separately.Cohort study. Stamm B et al., 2022 (JBMR Plus). PMID 35229064 ↗
- A pharmacovigilance analysis of spontaneously reported events across vitamin D receptor agonists, which names dihydrotachysterol within that drug class; spontaneous reports show what was reported, not how often events occur.Pharmacovigilance database analysis. Gáll Z et al., 2024 (Pharmaceuticals). PMID 39770528 ↗
These are the studies our verdict leans on, chosen from the 2 we read for Dihydrotachysterol. The full linked list is below.
Problems people have reported.
Read this carefully. These are 144 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Dihydrotachysterol is, not how risky it is. A report is not proof Dihydrotachysterol caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.